DCPH News and Press, Deciphera Pharmaceuticals Inc. From 07/06/22

Gainers: Option Care Health ( OPCH ) +8% . Bed Bath & Beyond ( BBBY ) +6% . Deciphera Pharmaceuticals ( DCPH ) +5% . GoodRx Holdings ( GDRX ) +4% . Redfin Corporation ( RDFN ) +4% . Losers: MIND Technology ( MINDP ...

Gainers: Inhibrx ( INBX ) +5% . Maxeon Solar Technologies ( MAXN ) +4% . Applied Molecular Transport ( AMTI ) +4% . Enovix Corporation ( ENVX ) +3% . Malibu Boats ( MBUU ) +3% . Losers: Kornit Digital ( KRNT ) -21% ...

Deciphera Pharmaceuticals (NASDAQ:DCPH) appointed Kelley Dealhoy as senior vice president and chief business officer. Waltham, Mass.-based Deciphera said in a June 16 release that Dealhoy is joining from Novartis (NVS), where she served for 10 years in different roles, most recently as v...

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced the appointment of Kelley Dealhoy as Senior Vice President and Chief Business Officer. Ms. Dealhoy brings 20 years of life science leadership experience to the role, and her responsibilities will include developing and leadi...

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that members of the management team will participate in fireside chats at the following investor conferences: Jefferies Healthcare Conference on June 9, 2022 at 10:00 AM ET in New York, NY JMP Securities Life Scien...

Deciphera Pharmaceuticals, Inc. (DCPH) Q1 2022 Earnings Conference Call May 04, 2022, 08:00 ET Company Participants Margarida Duarte - SVP & Head, International Steven Hoerter - President, CEO & Director Daniel Martin - SVP & Chief Commercial Officer Matthew Sherman - EVP & Ch...

Deciphera Pharmaceuticals press release (NASDAQ:DCPH): Q1 GAAP EPS of -$0.80 beats by $0.05. Revenue of $29.2M (+15.9% Y/Y) beats by $2.03M. For further details see: Deciphera Pharmaceuticals GAAP EPS of -$0.80 beats by $0.05, revenue of $29.2M beats by $2.03M

– First Quarter 2022 Revenue of $29.2 Million – – Net Proceeds of $163.4 Million from Public Offering in April, Enabling the Company to Fund Operating and Capital Expenditures into 2025 – – Pivotal Phase 3 MOTION Study of Vimseltinib ...

ABC,AMRN,AMRX,ASC,ATI,AVA,AVNS,BDC,BIP,BLX,BRKR,BRY,BWA,CDW,CFMS,CGAU,CLDT,CLH,CLVS,CMLS,CRL,CRTO,CSII,CVS,DCPH,DIN,DOC,OTCPK:EADSF,EAT,EDIT,EMR,OTCPK:ENLAY,EXPI,EYPT,FDP,FMS,OTCPK:FSNUF,FTS,FUN,GEL,GNRC,GOLD,GTHX,HZNP,IDXX,IMKTA,INSW,IONS,ISEE,JCI,JHG,OTCPK:LBLCF,LITE,LL,LNG,MAR,MCRB,MFA,MIR...

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its first quarter 2022 financial results on Wednesday, May 4, 2022. In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 8:00 AM ...